Advertisement
Advertisement
U.S. markets open in 6 hours 1 minute
Advertisement
Advertisement
Advertisement
Advertisement

Stealth BioTherapeutics Corp (MITO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3013+0.0133 (+4.62%)
At close: 04:00PM EDT
0.3000 -0.00 (-0.43%)
After hours: 05:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Slow Stochastic

Slow Stochastic

Previous Close0.2880
Open0.2900
Bid0.0000 x 4000
Ask0.0000 x 1100
Day's Range0.2830 - 0.3050
52 Week Range0.1620 - 1.5800
Volume827,311
Avg. Volume2,497,119
Market Cap22.16M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MITO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Stealth BioTherapeutics Corp.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    2 months agoMorningstar
View more
Advertisement
Advertisement